Catheter Precision Secures LockeT Orders and First German VIVO Placement
Fort Mill, S.C. – August 27, 2026 Catheter Precision, Inc. announced several commercial milestones for its LockeT® and VIVO™...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Fort Mill, S.C. – August 27, 2026 Catheter Precision, Inc. announced several commercial milestones for its LockeT® and VIVO™...
PRATTELN, Switzerland, July 13, 2026 Santhera Pharmaceuticals announced the expansion of its exclusive distribution agreement with Biomedica, extending commercial...
Calgary, Alberta — November 18, 2025 — Resverlogix Corp. (TSX: RVX), a late-stage biotechnology firm specializing in epigenetic therapies,...
RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
